On 11 January 2020, the genome sequence of SARS-CoV-2 was published online by Chinese researchers. Within 48 hours, Moderna had designed a candidate mRNA vaccine encoding the viral spike protein; within 66 days the first dose was injected into a Phase 1 trial volunteer; within 11 months, Pfizer-BioNTech and Moderna mRNA vaccines had received emergency-use authorization, completed Phase 3 trials in tens of thousands of subjects, and begun mass distribution. The previous fastest vaccine development — for mumps, in the 1960s — had taken four years. The order-of-magnitude compression was not an emergency improvisation but the demonstration of a technology platform under development since the early 1990s. mRNA platforms are now an established class of vaccines and therapeutics, with applications in development for cancer, influenza, RSV, malaria, tuberculosis, autoimmune disease, and protein-replacement therapy.
An mRNA vaccine uses synthetic messenger RNA to instruct the patient's own cells to produce a target protein (typically a viral antigen); the host's immune system then trains on it, generating antibodies and T-cell responses against the actual pathogen. Platform components: the mRNA sequence is codon-optimized for human ribosomes; modified nucleosides (typically N1-methylpseudouridine, the Karikó-Weissman 2005 discovery recognized by the 2023 Nobel Prize in Physiology or Medicine) let the synthetic mRNA evade innate-immune detection and reach ribosomes intact; a 5' cap and 3' poly-A tail enable translation; a lipid-nanoparticle (LNP) delivery vehicle carries the mRNA into muscle and antigen-presenting cells after intramuscular injection. The manufacturing advantage is enormous: where egg-based flu vaccines require months of fertilized eggs and live-virus growth, mRNA vaccines need only an in vitro transcription reaction (T7 RNA polymerase + DNA template), enzymatic capping, and LNP encapsulation — all in days on standardized equipment, with capacity scaling by adding bioreactors. Katalin Karikó spent decades against institutional skepticism until her 2005 nucleoside discovery with Drew Weissman solved the innate-immune problem; BioNTech (2008) and Moderna (2010) were built around the platform with cancer vaccines as the original commercial focus before COVID accelerated what was almost ready. Beyond COVID, applications stretch across infectious disease and oncology — cancer vaccines (Moderna's mRNA-4157 with pembrolizumab in Phase 3 for melanoma), influenza (quadrivalent and pentavalent mRNA flu in late-stage trials), and RSV (Moderna's mRESVIA, FDA-approved 2024). Self-amplifying mRNA requires lower doses, and the same LNP delivery is being repurposed for CRISPR delivery and targeted oncology.
The 2023 Nobel Prize went jointly to Katalin Karikó and Drew Weissman for the modified-nucleoside discovery that made mRNA vaccines deployable. Moderna and BioNTech (with Pfizer) shipped billions of doses during COVID-19, demonstrating manufacturing scalability no other platform has matched. mRNA cancer vaccines are the most advanced therapeutic application beyond infectious disease — Moderna's mRNA-4157 is in Phase 3 for melanoma adjuvant therapy with FDA breakthrough designation, and personalised neoantigen vaccines (mRNA encoding tumour-specific peptides identified by sequencing the patient's own cancer) are an active area. Self-amplifying mRNA (Replicate Bioscience, Gritstone, Strand Therapeutics) requires much lower doses; in situ CAR-T using mRNA to reprogram T cells inside the patient is in early clinical trials. The South African mRNA Hub and BioNTech's BioNTainer modular plants are transferring capacity to lower-income countries.